...As we gather a more complete dataset over time, we expect these results to ultimately conclude that the impact of these drugs on the market should not only be manageable but ultimately help drive awareness of the disease and fuel an increase in the number of patients who ultimately are offered various forms of treatment in this case, positive airway pressure, Andrew wrote in a report published on April 18 based on a conversation with Carlos Nunez, MD, ResMeds chief medical officer, about the SURMOUNT-OSA trial results
Multiple randomised, placebo-controlled trials have tested GLP-1 drugs as add-on therapy to insulin in people with T1D, and the picture that emerges is consistent, if modest: meaningful weight loss, real reductions in daily insulin needs, and improvements in CGM time in range
In some regions, Melanotan 2 is considered a controlled substance or unauthorized in the general population for human use due to safety concerns and regulatory restrictions
Its all about smart steps, not shortcuts.